{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:06:21Z","timestamp":1792839981113,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002081","name":"Irish Research Council","doi-asserted-by":"publisher","award":["GOIPG\/2017\/927"],"award-info":[{"award-number":["GOIPG\/2017\/927"]}],"id":[{"id":"10.13039\/501100002081","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001634","name":"National University of Ireland - Galway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.biopha.2021.111702","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T05:04:13Z","timestamp":1621227853000},"page":"111702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity"],"prefix":"10.1016","volume":"140","author":[{"given":"David S.","family":"Monahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimhear","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry P.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2021.111702_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib2","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"11","key":"10.1016\/j.biopha.2021.111702_bib4","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.biopha.2021.111702_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy \u2013 an update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2021.111702_bib7","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"13","key":"10.1016\/j.biopha.2021.111702_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.111702_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/CMAR.S47238","article-title":"Dexrazoxane for the treatment of chemotherapy-related side effects","volume":"6","author":"Langer","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.biopha.2021.111702_bib10","unstructured":"Questions and answers on the review of dexrazoxane-containing medicines, powder for solution for infusion, 500\u2009mg, Outcome of a procedure under Article 31 of Directive 2001\/83\/EC as amended, (2011)."},{"key":"10.1016\/j.biopha.2021.111702_bib11","unstructured":"Questions and answers on Cardioxane (dexrazoxane, powder for solution for injection, 500 mg) Outcome of a procedure under Article 13 of Regulation (EC) No 1234\/2008, (2017)."},{"issue":"36","key":"10.1016\/j.biopha.2021.111702_bib12","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ES)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2021.111702_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","article-title":"Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease","volume":"25","author":"Tebbi","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2004.02.031","article-title":"Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury","volume":"489","author":"Cao","year":"2004","journal-title":"Eur. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2021.111702_bib15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.freeradbiomed.2009.03.011","article-title":"Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway","volume":"46","author":"Danz","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2021.111702_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2015.03.438","article-title":"SIRT1 activation rescues doxorubicin-induced loss of functional competence of human cardiac progenitor cells","volume":"189","author":"De Angelis","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.biopha.2021.111702_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bcp.2018.02.025","article-title":"Resveratrol suppresses doxorubicin-induced cardiotoxicity by disrupting E2F1 mediated autophagy inhibition and apoptosis promotion","volume":"150","author":"Gu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2021.111702_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2016.01.002","article-title":"Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity","volume":"32","author":"Gu","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2021.111702_bib19","first-page":"260","article-title":"Reversal of doxorubicin-induced vascular dysfunction by resveratrol in rat thoracic aorta: Is there a possible role of nitric oxide synthase inhibition?","volume":"9","author":"Olukman","year":"2009","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.biopha.2021.111702_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1475-2867-13-52","article-title":"Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals","volume":"13","author":"Osman","year":"2013","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.biopha.2021.111702_bib21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/08880018.2012.762962","article-title":"Resveratrol and adipose-derived mesenchymal stem cells are effective in the prevention and treatment of doxorubicin cardiotoxicity in rats","volume":"30","author":"P\u0131narl\u0131","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1124\/jpet.111.189589","article-title":"Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy","volume":"341","author":"Xu","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2021.111702_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbadis.2014.10.016","article-title":"Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases","volume":"1852","author":"Zordoky","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/j.biopha.2021.111702_bib24","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/nu11030627","article-title":"Leveraging the cardio-protective and anticancer properties of resveratrol in cardio-oncology","volume":"11","author":"Abdelgawad","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.biopha.2021.111702_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181535","article-title":"Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity","volume":"12","author":"Shoukry","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.biopha.2021.111702_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail. Rev."},{"issue":"20","key":"10.1016\/j.biopha.2021.111702_bib27","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.biopha.2021.111702_bib28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","article-title":"Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity","volume":"122","author":"Kheiri","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"11\u201312","key":"10.1016\/j.biopha.2021.111702_bib29","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1089\/ten.tea.2014.0591","article-title":"Cardiomyoblast (h9c2) differentiation on tunable extracellular matrix microenvironment","volume":"21","author":"Suhaeri","year":"2015","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.biopha.2021.111702_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-020-00885-3","article-title":"Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities","author":"Monahan","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"41","key":"10.1016\/j.biopha.2021.111702_bib31","doi-asserted-by":"crossref","first-page":"29063","DOI":"10.1074\/jbc.274.41.29063","article-title":"Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells","volume":"274","author":"M\u00e9nard","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.111702_bib32","unstructured":"Pereira S., Gonzalez S., Gusev O., Branco A., Oliveira P., Rizvanov A. Gene expression profiling of H9c2 myoblast differentiation towards a cardiac-like phenotype."},{"issue":"2","key":"10.1016\/j.biopha.2021.111702_bib33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3892\/etm.2016.3437","article-title":"Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes","volume":"12","author":"Liu","year":"2016","journal-title":"Exp. Ther. Med."},{"issue":"2","key":"10.1016\/j.biopha.2021.111702_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","article-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","volume":"200","author":"Oliveira","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2021.111702_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3858\/emm.2009.41.3.020","article-title":"Resveratrol inhibits foam cell formation via NADPH oxidase 1- mediated reactive oxygen species and monocyte chemotactic protein-1","volume":"41","author":"Park","year":"2009","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2021.111702_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10715760802673008","article-title":"Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage","volume":"43","author":"Tatlidede","year":"2009","journal-title":"Free Radic. Res."},{"issue":"1","key":"10.1016\/j.biopha.2021.111702_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","article-title":"Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes","volume":"523","author":"Yu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2021.111702_bib38","article-title":"Dexrazoxane protects cardiomyocyte from doxorubicin-induced apoptosis by modulating miR-17-5p","volume":"2020","author":"Yu","year":"2020","journal-title":"BioMed Res. Int."},{"issue":"6","key":"10.1016\/j.biopha.2021.111702_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MPH.0000000000001118","article-title":"Dexrazoxane significantly reduces anthracycline-induced cardiotoxicity in pediatric solid tumor patients: a systematic review","volume":"40","author":"Liesse","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2021.111702_bib40","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/molecules22101589","article-title":"Aspalathin reverts doxorubicin-induced cardiotoxicity through increased autophagy and decreased expression of p53\/mTOR\/p62 signaling","volume":"22","author":"Johnson","year":"2017","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2021.111702_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1476-5381.2011.01208.x","article-title":"Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity","volume":"163","author":"Spagnuolo","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2021.111702_bib42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.nutres.2012.07.002","article-title":"Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action","volume":"32","author":"Xu","year":"2012","journal-title":"Nutr. Res."},{"key":"10.1016\/j.biopha.2021.111702_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221004844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221004844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:07:38Z","timestamp":1774530458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221004844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S0753332221004844"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111702","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111702"}}